NDV-01
Non-Muscle Invasive Bladder Cancer (NMIBC)
Key Facts
About Relmada Therapeutics
Relmada Therapeutics is a publicly traded biotech firm focused on developing differentiated therapies that combine durable efficacy, favorable safety, and ease of administration. With a seasoned leadership team and a strong financial foundation bolstered by recent financing, the company is executing on a strategic pipeline anchored by NDV-01 for bladder cancer and sepranolone for compulsive disorders. Relmada's approach prioritizes clinical validation, clear development pathways, and addressing well-defined patient populations to create long-term value.
View full company profileAbout Relmada Therapeutics
Relmada Therapeutics is a publicly traded biotech firm focused on developing differentiated therapies that combine durable efficacy, favorable safety, and ease of administration. With a seasoned leadership team and a strong financial foundation bolstered by recent financing, the company is executing on a strategic pipeline anchored by NDV-01 for bladder cancer and sepranolone for compulsive disorders. Relmada's approach prioritizes clinical validation, clear development pathways, and addressing well-defined patient populations to create long-term value.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Dabogratinib (Onc) | Tyra Biosciences | Phase 2 |
| Vesique® (APL-1202) | Asieris Pharmaceuticals | Phase 3 |